OBJECTIVE

Keeping in view the fact that anti-seizure drugs (ASDs) can frequently reduce pain in various animal models of inflammatory and neuropathic pain, the potential of N’-[4-(4-fluorophenoxy)benzylidene]pyridine-4-carbohydrazide PCH 6 and N-(4-methoxyphenyl)-2-[4-(4-methylphenoxy)benzylidene] hydrazine carbothioamide PT 30 to alleviate the acute and/or inflammatory stages of pain was assessed in mouse formalin test of hyperalgesia.

MATERIAL AND METHODS

Since, neuropathic pain represents pathological states of abnormal neuronal discharge; the potentials of PCH 6 and PT 30 to alleviate the acute and/or inflammatory stages of pain were estimated in mouse formalin test of hyperalgesia

RESULTS

PCH 6 and PT 30 were designed, synthesized and established as a prospective anticonvulsant compounds. PCH 6 and PT 30 exhibited significant anticonvulsant activity in two seizure models namely MES and 6 Hz seizure. At a dose close to MES ED₅₀, PCH 6 exhibited notable reduction in paw licking behavior of mice during the acute and inflammatory stages ensuing formalin injection in the paw. At a dose of 128 mg/kg, PCH 6 showed 61.71% control (SEM 7.525; p>0.05) in acute stage and 15.49% control (SEM 10.81; p>0.01) in inflammatory stage of pain in the mouse formalin test of hyperalgesia. At a dose of 100 mg/kg, PT 30 displayed considerable curtailment in paw licking behavior of mice during the acute and inflammatory phases ensuing formalin injection in the paw. PT 30 showed 61.57% control (SEM 7.71; p>0.05) in acute stage and 6.03% control (SEM 2.98; p>0.01) in the inflammatory stage of pain in the mouse formalin test of hyperalgesia.

CONCLUSION

PCH 6 and PT 30 turned up as an effectual anti-hyperalgesic in mouse formalin test and can be explored as a prototype in the development of analgesic and anti-inflammatory agent for control of pain in neuropathic pain syndrome.